 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2654-------------------------------------------------- |
|
(ECTRIMS) Early Ocrevus use in PPMS slows disability risk, inclu |
|
ding risk of wheelchair reliance |
|
By: agate Date: September 18, 2019, 1:44 am |
|
--------------------------------------------------------- |
|
Hmm. No sooner has an announcement touting Mayzent (siponimod) |
|
as helpful in delaying the need for a wheelchair for persons |
|
with SPMS than it turns out that Ocrevus (ocrelizumab) can also |
|
help to keep the dreaded wheelchair away--though the claim here |
|
is for PPMS. From Multiple Sclerosis New Today (September 17, |
|
2019)--"ECTRIMS 2019: Early Ocrevus Use in PPMS Slows Risk of |
|
Disability, Including Risk of Wheelchair Reliance." |
|
https://multiplesclerosisnewstoday.com/news-posts/2019/09/06/ectrims2019-early-… |
|
#Post#: 2658-------------------------------------------------- |
|
Re: (ECTRIMS) Genentech reports Ocrevus living up to expectation |
|
s |
|
By: agate Date: September 19, 2019, 11:44 pm |
|
--------------------------------------------------------- |
|
A more comprehensive overview of some of the Ocrevus material |
|
presented at the ECTRIMS conference--again, from Multiple |
|
Sclerosis News Today (September 19). The spokespeople are drug |
|
company representatives. There have been 7 PML cases so far, |
|
according to the article, but they are careful to point out |
|
these were all "carryover cases": |
|
http://bit.ly/2kmpBr4 |
|
***************************************************** |
